Salt Lake City Precision Oncology Symposium

Salt Lake City, UT US
November 4, 2023

This program, the Salt Lake City Precision Oncology Symposium, is an accredited continuing education activity designed to improve the care of cancer patients by educating cancer care providers about precision oncology. This oncology conference features leading experts in the field of precision oncology who will provide a comprehensive overview of the implications of actionable molecular alterations across common malignancies.
This activity is designed to facilitate learning, improve knowledge retention, and inspire participants to implement the newly acquired knowledge into their clinical practice. Through didactic lectures, case-based discussions, and interactive questions and answer sessions, participants will be able to ask relevant questions, clarify concerns, and network with expert faculties. 

Target Audience

  • Hematologists/ Oncologists
  • Oncology Fellows
  • NPs/PAs
  • Pharmacists
  • Nurses
  • Researchers and others

Organizing Committee

Conference Director: 

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chair: 

Glynn W. Gilcrease, MD - University of Utah Huntsman Cancer Institute

Planning Committee: 

Jonathan R. Whisenant, MD Intermountain Health

Benjamin L. Maughan, MD, PharmD - University of Utah Huntsman Cancer Institute

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Identify frequent molecular abnormalities across several common malignancies and understand the appropriate timing of testing to detect these abnormalities.
  • Interpret results of next-generation sequencing and other biomarkers predictive of response to targeted therapies and recognize the challenges involved.
  • Explain the role, including advantages and disadvantages, of different testing methodologies available for the selection of targeted therapies. 
  • Plan optimal molecular-targeted treatment strategies for the treatment of cancer.
  • Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in the clinical investigation of cancer patients.
Course summary
Available credit: 
  • 6.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.25 Contact Hours.
Course opens: 
07/27/2023
Course expires: 
01/06/2024
Event starts: 
11/04/2023 - 8:00am PDT
Event ends: 
11/04/2023 - 4:30pm PDT
Cost:
$100.00

November 04, 2023

All times are listed in Mountain Daylight Time (MDT)

07:00 – 08:00 AM: REGISTRATION, BREAKFAST, EXHIBITS


08:00 – 08:05 AM: Welcome - Glynn W. Gilcrease, MD

08:05 – 08:25 AM: Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD


08:25 – 09:10 AM: SESSION 1 - PRECISION ONCOLOGY – GENERAL CONCEPTS

Moderator: Glynn W. Gilcrease, MD

08:25 – 08:40 AM: Solid Tumor Genomic Testing - Benjamin Maughan MD, PharmD

08:40 – 08:55 AM: Liquid Biopsy - Glynn W. Gilcrease, MD

08:55 – 09:10 AM: Q and A


09:10 – 10:10 AM: SESSION 2 - GI ONCOLOGY

Moderator: Glynn W. Gilcrease, MD

09:10 – 09:25 AM: Keynote Lecture - Jonathan Whisenant, MD

09:25 – 10:10 AM: Panel Discussion - Glynn W. Gilcrease, MD; Jonathan Whisenant, MD; Kristin E. Barber, APRN, AOCNP, FNP-BC; Khaled Alhamad, MD


10:10 – 10:30 AM: BREAK AND EXHIBITS


10:30 – 11:30 AM: SESSION 3 - BREAST CANCER

Moderator: Fengting Yan, MD, FACP

10:30 – 10:45 AM: Genomics in Breast Cancer - Mei Wei, MD

10:45 – 11:30 AM: Panel Discussion - Kristen C. Kelley, MD


11:30 AM – 12:30 PM: LUNCH AND EXHIBITS


12:30 – 01:30 PM: SESSION 4 - GU ONCOLOGY

Moderator: Benjamin Maughan, MD, PharmD

12:30 – 12:45 PM: Keynote Speech - David Gill, MD

12:45 – 01:30 PM: Panel Discussion - Umang Swami, MD, MS; Vinay Mathew Thomas, MBBS


01:30 – 02:30 PM: SESSION 5 - LUNG CANCER

Moderator: Rafael Santana-Davila, MD

01:30 – 01:45 PM: Keynote Speech - Sonam Puri, MD

01:45 – 02:30 PM: Panel Discussion - Sonam Puri, MD; Jessica Campaign-Mauser, PharmD, BCOP


02:30 – 03:00 PM: BREAK AND EXHIBITS


03:00 – 04:00 PM: SESSION 6 - HEMATOLOGY

Moderator: Srinivas K. Tantravahi, MBBS

03:00 – 03:15 PM: Multiple Myeloma - Manni Mohyuddin, MD

03:15 – 03:30 PM: Myeloid Disorders - Ami Patel, MD

03:30 – 04:00 PM: Case-Based Presentations - Madhu Menon, MD, PhD; Kelsey Baron, MD

Hilton Salt Lake City Center
255 South West Temple
Salt Lake City, UT 84101
United States

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

G. Weldon Gilcrease

has no relevant financial relationships to disclose at this time.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Khaled Alhamad, Hematology/Oncology Fellow

has no relevant financial relationships to disclose at this time.

Kristin Barber, AOCNP-FNP-BC

has a financial relationship (Professional Services) with Merck;.

G. Weldon Gilcrease

has no relevant financial relationships to disclose at this time.

Kristen Kelley, MD

has no relevant financial relationships to disclose at this time.

Vinay Mathew Thomas

has no relevant financial relationships to disclose at this time.

Madhu Menon, MD, PhD, FCAP, FASCP

has no relevant financial relationships to disclose at this time.

Ghulam Rehman Mohyuddin, MD

has no relevant financial relationships to disclose at this time.

Ami Patel

has a financial relationship (Grant Or Contract) with Genentech Roche;.

Umang Swami, MD, MS

has a financial relationship (Other) with Exelixis;.
has a financial relationship (Other) with Sanofi ;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with ImVax;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Seattle Genetics;.
has a financial relationship (Other) with AstraZeneca ;.

Mei Wei, MD

has a financial relationship (Other) with Gilead Science;.

Jonathan Whisenant, MD

has no relevant financial relationships to disclose at this time.
Case Presenter(s)

Kelsey Baron

has no relevant financial relationships to disclose at this time.

Jessica Campaign-Mauser, PharmD, BCOP

has no relevant financial relationships to disclose at this time.
Moderator(s)

David Gill, MD

has a financial relationship (Professional Services) with Myovant;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Eisai;.
has a financial relationship (Professional Services) with Janssen;.

Benjamin Maughan, M.D., PharmD

has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Bristol-Myers Squibb;.
has a financial relationship (Independent contractor) with Exelixis;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Tempus;.
has a financial relationship (Independent contractor) with Peloton Therapeutis;.
has a financial relationship (Independent contractor) with AVEO Oncology;.
has a financial relationship (Independent contractor) with Clovis;.
has a financial relationship (Independent contractor) with Bayer Oncology;.

Sonam Puri, MD

has a financial relationship (Professional Services) with Pfizer ;.
has a financial relationship (Professional Services) with G1 therapeutics ;.
has a financial relationship (Professional Services) with Jazz Pharmaceuticals ;.

Rafael Santana-Davila, MD

has no relevant financial relationships to disclose at this time.

Srinivas Tantravahi, MBBS; MRCP

has a financial relationship (Professional Services) with CTI BioPharma;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Financial Support) with karyopharm therapeutics;.
has a financial relationship (Professional Services) with MorphoSys;.

Fengting Yan, MD

has no relevant financial relationships to disclose at this time.

Available Credit

  • 6.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.25 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$100.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.